These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

83 related articles for article (PubMed ID: 21475131)

  • 61. Carboplatin Dosing on the Basis of Renal Function: 30+ Years after Calvert.
    Schwenk MH
    Kidney360; 2024 Feb; 5(2):271-273. PubMed ID: 38233985
    [No Abstract]   [Full Text] [Related]  

  • 62. Corrigendum to 'Glomerular filtration rate estimation for carboplatin dosing in patients with gynaecological cancers': [ESMO Open volume 7 (2022) 10.1016/j.esmoop.2022.100401].
    Samani A; Bennett R; Eremeishvili K; Kalofonou F; Whear S; Montes A; Kristeleit R; Krell J; McNeish I; Ghosh S; Tookman L
    ESMO Open; 2023 Jun; 8(3):100640. PubMed ID: 37071958
    [No Abstract]   [Full Text] [Related]  

  • 63. [Determination of individual kidney function?].
    Lipp HP
    Med Monatsschr Pharm; 2008 Oct; 31(10):393-5. PubMed ID: 18975414
    [No Abstract]   [Full Text] [Related]  

  • 64. Carboplatin dosing in children: calculation by different formulae.
    Würthwein G; Krefeld B; Gerss J; Boos J
    Onkologie; 2011; 34(1-2):16-22. PubMed ID: 21346380
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Evaluation of predictive formulae for glomerular filtration rate for carboplatin dosing in gynecological malignancies.
    de Lemos ML; Hsieh T; Hamata L; Levin A; Swenerton K; Djurdjev O; Vu T; Hu F; Conklin J; Malfair Taylor SC
    Gynecol Oncol; 2006 Dec; 103(3):1063-9. PubMed ID: 16875719
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Carboplatin dosing accounting for the renal and hematologic status of patients.
    Busse T
    Clin J Oncol Nurs; 2003; 7(1):104-5. PubMed ID: 12629944
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Evaluation of creatinine-based formulas in dosing adjustment of cancer drugs other than carboplatin.
    Jennings S; de Lemos ML; Levin A; Murray N
    J Oncol Pharm Pract; 2010 Jun; 16(2):113-9. PubMed ID: 19578094
    [TBL] [Abstract][Full Text] [Related]  

  • 68. [Pharmacokinetics and individual dose adjustment of carboplatin].
    Chatelut E; Canal P; Bugat R
    Bull Cancer; 2000 Aug; 87 Spec No():17-23. PubMed ID: 11082718
    [TBL] [Abstract][Full Text] [Related]  

  • 69. [The kidney in children under chemotherapy].
    Cachat F; Guignard JP
    Rev Med Suisse Romande; 1996 Dec; 116(12):985-93. PubMed ID: 9026889
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Comparative clinical pharmacology of cisplatin and carboplatin.
    Murry DJ
    Pharmacotherapy; 1997; 17(5 Pt 2):140S-145S. PubMed ID: 9322881
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Chemotherapy dosing part II: alternative approaches and future prospects.
    Kaestner SA; Sewell GJ
    Clin Oncol (R Coll Radiol); 2007 Mar; 19(2):99-107. PubMed ID: 17355104
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Current dilemmas in carboplatin dosing.
    Ratain MJ
    Clin Adv Hematol Oncol; 2011 Mar; 9(3):237-8. PubMed ID: 21475131
    [No Abstract]   [Full Text] [Related]  

  • 73.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 74.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 75.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 76.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 77.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 78.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 79.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 80.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.